BMY Surges 5% Premarket on AstraZeneca Merger Talks and Raised 2026 Guidance
BMY sits 61% above its 52-week low of $42.52.
Summary
Bristol-Myers Squibb shares jumped ~4.5–5% in premarket trading after reports of advanced merger talks with AstraZeneca, which would create a $400B pharma giant. This follows last week's massive Q2 beat—revenue of $12.97B and adjusted EPS of $2.04—and a raised 2026 outlook to $6.75–7.00 EPS on $49–50B revenue. The merger speculation adds a new layer of upside, though antitrust concerns are noted. The stock is already trading near its 52-week high, reflecting strong momentum from both the earnings beat and deal chatter.
At the time of this announcement, BMY was trading at $68.50 on NYSE in the Life Sciences sector, with a market capitalization of approximately $133.4B. The 52-week trading range was $42.52 to $65.66. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.